Compare UNFI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNFI | NRIX |
|---|---|---|
| Founded | 1976 | 2009 |
| Country | United States | United States |
| Employees | 23431 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | UNFI | NRIX |
|---|---|---|
| Price | $53.37 | $13.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $52.72 | $33.50 |
| AVG Volume (30 Days) | 444.6K | ★ 3.3M |
| Earning Date | 12-08-2026 | 10-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 168.72 | N/A |
| EPS | 1.34 | ★ 3.26 |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $1.25 | $786.93 |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | $38.81 | ★ $4.37 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $30.91 | $14.01 |
| 52 Week High | $57.02 | $28.23 |
| Indicator | UNFI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 22.74 |
| Support Level | $44.57 | N/A |
| Resistance Level | $57.02 | $17.47 |
| Average True Range (ATR) | 1.89 | 1.12 |
| MACD | 0.58 | -0.63 |
| Stochastic Oscillator | 96.79 | 0.15 |
United Natural Foods Inc is a wholesale distributor of natural, organic, and specialty foods and nonfood products across the United States and Canada. The company's products consist of national, regional, and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's reportable segments are: Natural (its maximum revenue-generating segment), Retail, and Conventional.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.